RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit

Rhea-AI Summary

RAPT Therapeutics, Inc. (Nasdaq: RAPT) announced the presentation of clinical efficacy data from its Phase 1b trial of RPT193, an oral CCR4 inhibitor for moderate-to-severe atopic dermatitis. The presentation will occur at the 4th Inflammatory Skin Disease Summit in New York, from November 3-6, 2021. The trial is designed to demonstrate the efficacy of RPT193 compared to a placebo. This is part of RAPT's commitment to developing therapies for significant unmet needs in oncology and inflammatory diseases.

Positive

• Upcoming presentation of Phase 1b trial data for RPT193 highlights potential efficacy in treating atopic dermatitis.
• RAPT is advancing its CCR4 targeting drug candidates, which could fulfill unmet medical needs.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that it will present additional clinical efficacy data from its Phase 1b monotherapy trial of RPT193 in patients with moderate-to-severe atopic dermatitis at the 4th Inflammatory Skin Disease Summit to be held November 3-6, 2021 in New York, NY.

Presentation details as follows:

Title:	RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis
Date & Time:	November 3, 2021, 5:00 – 5:30 p.m. EST
Presenter:	Robert Bissonnette, MD, FRCPC, Chief Executive Officer and Medical Director of Innovaderm Research Inc.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the progress of RAPT’s oncology and inflammation programs and the interpretation of topline results from the Phase 1b trial of RPT193. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT’s Form 10-Q filed with the Securities and Exchange Commission on August 11, 2021 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

FAQ

What is the significance of RAPT's upcoming presentation on RPT193?

The presentation at the 4th Inflammatory Skin Disease Summit will provide crucial efficacy data from the Phase 1b trial, which could impact investor sentiment and stock performance.

When is the RPT193 clinical data presentation scheduled?

The presentation is scheduled for November 3, 2021, from 5:00 – 5:30 p.m. EST.

What is RPT193 and its relevance in clinical trials?

RPT193 is an oral CCR4 inhibitor being tested for its efficacy in treating moderate-to-severe atopic dermatitis, addressing a critical area in dermatological treatment.

What company is behind RPT193?

RAPT Therapeutics, a clinical-stage biopharmaceutical company, is developing RPT193 for inflammatory diseases.